Actinium Pharmaceuticals Inc ATNM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Actinium Pharmaceuticals to Host KOL Webinar on ATNM-400, a First-in-Class HER3-Targeted Alpha Radiotherapy
Actinium Pharmaceuticals Announces Enrollment in the RADIANZ Imaging Clinical Trial Intended to Demonstrate the Pan-Cancer Potential of ATNM-400, A First-in-Class HER3-Targeting Radiotherapy
Actinium Pharmaceuticals Announces Three ASH 2026 Abstracts Highlighting Iomab-ACT Clinical Results in CAR T-Cell Therapy and Sickle Cell Disease
Actinium Pharmaceuticals Announces ASH 2026 Abstract Highlighting Long-Term Results of Actimab-A in Combination with CLAG-M in Relapsed or Refractory AML
Actinium Pharmaceuticals Announces Inducement Grant to New Employee
Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026
Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer
Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models
Trading Information
- Previous Close Price
- $1.49
- Day Range
- $1.28–1.49
- 52-Week Range
- $0.74–1.72
- Bid/Ask
- $1.28 / $1.56
- Shares Outstanding
- 31.44M
- Market Cap
- $42.45M
- Volume/Avg
- 553,295 / 186,234
Key Statistics
- Price/Earnings (Normalized)
- 4.26
- Price/Sales
- 1.33
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 25
Valuation
Metric | ATNM |
|---|---|
Price/Earnings (Normalized) | 4.26 |
Price/Book Value | 1.91 |
Price/Sales | 1.33 |
Price/Cash Flow | 3.97 |
Price/Earnings
ATNM
Financial Strength
Metric | ATNM |
|---|---|
Quick Ratio | 3.89 |
Current Ratio | 4.00 |
Interest Coverage | — |
Quick Ratio
ATNM
Profitability
Metric | ATNM |
|---|---|
Return on Assets (Normalized) | 23.90% |
Return on Equity (Normalized) | 68.52% |
Return on Invested Capital (Normalized) | 56.65% |
Return on Assets
ATNM
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|>jN%Mwf | LOCK|!Y&%Z | $136B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|#dr?zhP | LOCK|$P!@P | $99B | |||
| Moderna Inc MRNA | LOCK|nfh@>Rz | LOCK|?q | $87B | |||
| argenx SE ADR ARGX | LOCK|Knp?%>R | LOCK|^@< | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|gXJZ>R | LOCK|Klz | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|&!MNzFV | LOCK|G&V? | $31B | |||
| Incyte Corp INCY | LOCK|>^Cfjm | LOCK|?WH | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|XhvlNcT | LOCK|&d@@ | $21B | |||
| BioNTech SE ADR BNTX | LOCK|K$P<?<D | LOCK|yPX | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|Crqxh@ | LOCK|>FQ | $15B |